Virpax Pharmaceuticals, Inc. (VRPX)

NASDAQ: VRPX · IEX Real-Time Price · USD
1.71
+0.14 (8.92%)
Jun 29, 2022 11:46 AM EDT - Market open
8.92%
Market Cap 20.03M
Revenue (ttm) n/a
Net Income (ttm) -14.81M
Shares Out 11.71M
EPS (ttm) -1.72
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 246,150
Open 1.61
Previous Close 1.57
Day's Range 1.50 - 1.71
52-Week Range 1.19 - 36.00
Beta n/a
Analysts n/a
Price Target 4.08 (+138.6%)
Earnings Date Aug 9, 2022

About VRPX

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical nonsteroidal anti-inflammatory drug treatment for chronic osteoarthritis of the knee; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nan... [Read more...]

Industry Biotechnology
IPO Date Feb 17, 2021
Employees 7
Stock Exchange NASDAQ
Ticker Symbol VRPX
Full Company Profile

Financial Performance

Financial Statements

News

Virpax Will Pursue Direct to OTC Pathway for Epoladerm™ for Pain Associated with Osteoarthritis

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-tr...

Virpax Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. (“Virpax”) (NASDAQ: VRPX), a company specializing in product candidates for pain management, CNS disorders and anti-viral indication...

Virpax Pharmaceuticals Reports 2022 First Quarter Results and Recent Developments

BERWYN, Pa.--(BUSINESS WIRE)-- #earnings--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), today announced its financial results for the quarter ended March 31, 2022, and other r...

Virpax Pharmaceuticals Enters Into CRADA With The U.S. Army Institute of Surgical Research

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-tr...

Virpax Successfully Completes Initial Preclinical Studies for VRP324

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive product candidates for pain managemen...

Virpax Pharmaceuticals Reports 2021 Year-End Results

BERWYN, Pa.--(BUSINESS WIRE)-- #earnings--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), today announced its financial results for the twelve months ended December 31, 2021, an...

Virpax Completes All FDA-Required Pre-Clinical Studies for Epoladerm™

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management Post-Tra...

Nanomerics Receives Further Upfront Payment for Anti-Viral Spray AnQlar(TM)

LONDON, UK / ACCESSWIRE / March 22, 2022 / Nanomerics Ltd., a private speciality pharmaceutical company, today announced the receipt of a further milestone payment on agreeing the expansion of its anti-...

Virpax Pharma Expands AnQlar Worldwide Licensing Pact In COVID-19

Virpax Pharmaceuticals Inc (NASDAQ: VRPX) expanded its exclusive license agreement for AnQlar with Nanomerics Ltd, providing Virpax with the worldwide rights for development and commercialization. Virpa...

Virpax Pharmaceuticals Expands AnQlar™ Development and Commercialization Rights Through Worldwide Licensing Agreement

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive product candidates for pain managemen...

News Outlets Highlight Virpax Pharmaceuticals and Its Potential Solutions for the Opioid Crisis and COVID-19

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive product candidates for pain managemen...

Virpax Reports Favorable Preclinical Safety Data for Envelta™  for the Treatment of Acute and Chronic Pain

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive product candidates for pain managemen...

Altasciences Chosen by Virpax Pharmaceuticals, Inc. to Conduct First-in-Human Study of Epoladerm™ for Chronic Pain As...

LAVAL, Quebec--(BUSINESS WIRE)-- #Altasciences--Altasciences is pleased to have been chosen by Virpax® Pharmaceuticals, Inc. (“Virpax”) (NASDAQ:VRPX) to conduct a first-in-human study of Epoladerm™ (dic...

Virpax® Successfully Completes Preclinical Dermal Safety Studies for Epoladerm™

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorde...

Virpax Pharmaceuticals Recaps Milestones and Highlights Product Portfolio

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX) achieved significant milestones relating to its pipeline of product candidates as of the e...

Virpax Announces Clinical Trial Site in Canada for First in Human Study of Epoladerm™ for Pain Associated with Osteoa...

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorde...

4 Reddit Penny Stocks To Buy For Under $5 As Trump Stocks Jump

4 Reddit penny stocks to watch right now. The post 4 Reddit Penny Stocks To Buy For Under $5 As Trump Stocks Jump appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Other symbols: DATSPHUNPSFE

Virpax Reports Successful Results of Toxicology and Pharmacokinetic Study for Epoladerm™

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorde...

Virpax Pharmaceuticals Reports 2021 Third Quarter Results and Recent Developments

BERWYN, Pa.--(BUSINESS WIRE)-- #earnings--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), today announced its financial results for the three and nine months ended September 30,...

Virpax Advances Envelta™ Development with NCATS Under CRADA Agreement

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorde...

Virpax to Present at the NobleCon Online Pain Management Investor Forum on Channelchek.com on October 7, 2021

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), a company specializing in developing product candidates for pain management, CNS disorder...

Best Penny Stocks To Buy Today? Retail Traders Are Watching These Now

Penny stocks bouncing back after the stock market sell-off The post Best Penny Stocks To Buy Today? Retail Traders Are Watching These Now appeared first on Penny Stocks to Buy, Picks, News and Informati...

Other symbols: BESTCYDY

Virpax to Develop Intranasal Cannabidiol Product for the Management of Epilepsy in Adults and Children

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), a company specializing in developing product candidates for pain management, CNS disorder...

Virpax® Pharmaceuticals Announces Closing of $40 Million Public Offering of Common Stock

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), a company specializing in developing pharmaceutical products for pain management, today an...

Virpax® Pharmaceuticals Announces Pricing of $40 Million Public Offering of Common Stock

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), a company specializing in developing pharmaceutical products for pain management, today an...